Pharmaceutical

  • Industry-leading R&D capability
  • Trustworthy product quality
  • Sustainable supply capacity

Industry-leading R&D capability

Formulation Lab
Automatic Reaction Calorimeter
Analyzing Equipment
Fermentators 20-50L Pilot

Trustworthy product quality

Latest Inspection from the Agencies

Agency

Date

Items

Site

Results

 

 





 

Sept. 2023

Sitaglintin intermediate

Yonatai Site 2

Passed

Sept. 2019

Gabapentin, Carbidopa, Etedelac

Chiral Pharma

Passed

Oct, 2017

Gabapentin, Carbidopa, Etedolac

Chiral Pharma

Passed

Oct, 2018

Resuvastatin Tablet

Yongtai Pharma

Passed

March,2019

Doxycycline hydrochloride capsule Gabapentin capsule

Yongtai Pharma

Passed

Sept, 2016

Metoprolol Tatrate

Yongtai Pharma

Passed


 

Nov,2011

Gabapentin

Chiral Pharma

Passed

 




 

Aug,2019

Gabapentin

Chiral Pharma

Passed

Apri,2021

Duloxetine hydrochloride enteric capsule

Yongtai Pharma

Passed

Oct, 2021

Nevira flatten dispersible tablet

Yongtai Pharma

Passed

April, 2017

Methydopa

Yongtai Pharma

Passed

May,2017

Gabapentin, Carbidopa, Methyldopa

Chiral Pharma

Passed

Oct,2014

Gabapentin

Chiral Pharma

Passed


 

Jul,2012

Gabapentin

Chiral Pharma

Passed


 

Oct,2013

Methyldopa

Chiral Pharma

Passed

The company passed an FDA audit in 2023. It has also passed inspections from several agencies for various products in recent years, and the quality of its products can be trusted.

The company has a stable and reliable supply ability. Since 1999, Yongtai has served over 300 pharmaceutical customers and built business connections with 13 of the Top20 global pharmaceutical companies and most of the major generics. Additionally, the company has established long-term preferred partnership with 3 of the Top 20 Companies by being adaptive, responsive, transparent and cost-effective, delivering sustainable value.